FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
175 letters match. Newest first.
-
DrugsConroe Welding Supply, Inc.
FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).
High risk -
FoodIF Co-Pack, LLC dba Initiative Foods
FDA warns Initiative Foods, a Sanger, California baby food maker, that it failed to control patulin, a mold toxin, in fruit pouches.
High risk -
FoodLa Cabana Food Distributing, Inc.
FDA found Listeria in La Cabana Food Distributing's ready-to-eat salsa plant and cited sanitation and hazard analysis failures.
High risk -
DrugsTSP Solutions Pte. Ltd.
FDA warns Singapore OTC drug maker TSP Solutions over missing release testing and component identity checks for sunscreens.
High risk -
DrugsZhejiang Gaorong Cosmetic Co., Ltd.
FDA cited Zhejiang Gaorong Cosmetic for OTC drug CGMP violations in component testing and quality unit oversight.
High risk -
DrugsSnugZ USA, Inc.
SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.
High risk -
DrugsEurofins SF Analytical Laboratories, Inc.
FDA warned Eurofins SF Analytical Laboratories, a contract drug-testing lab, that it kept incomplete microbial test records and skipped required investigations.
High risk -
DrugsJiangmen Shuizirun Sanitary Articles Co., Ltd.
FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.
High risk -
DrugsTCI Co., Ltd BioCosme PABP BRANCH
FDA warns Taiwan OTC drug contract manufacturer TCI BioCosme over CGMP violations, including incomplete release and ingredient testing.
High risk -
DrugsBabikian Healthcare Products CJSC
FDA warns Babikian Healthcare Products over manufacturing quality failures for over-the-counter drugs, including missing identity and finished-product testing.
High risk -
DrugsCuria New York, Inc.
FDA warned Curia New York's Rensselaer, New York API plant that undocumented lab injections, shredded records and shared passwords violate CGMP.
High risk -
DrugsBentley Laboratories LLC
Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.
High risk -
DrugsVeganicSKN Limited
FDA warns VeganicSKN over manufacturing rule failures; drug shipped after failing test and high-risk ingredient not identity-tested.
High risk -
DrugsStream2Sea, LLC
FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.
Medium -
Drugskdc/one Chatsworth, Inc.
FDA warned kdc/one Chatsworth of CGMP violations in OTC drugs, including missing carcinogen testing and storage temperature failures.
High risk -
DrugsShoolin Pharma Chem LLP
Shoolin Pharma Chem, an Indian API maker, warned over filthy conditions, missing test data, and cleaning failures; all U.S. APIs recalled.
High risk -
DrugsSafrel Pharmaceuticals LLC
FDA warned Safrel Pharmaceuticals, an OTC drug labeler in Dayton, New Jersey, that it lacked quality oversight of its suppliers and shipped adulterated drugs.
High risk -
DrugsAHC Products, Inc.
AHC Products, Inc. was cited for manufacturing-rule violations and unapproved animal drugs, including AniPrin and Rot-B-Gone.
High risk -
DrugsSpa De Soleil, Inc.
FDA cites Spa De Soleil for CGMP violations in OTC topical drugs, including water system failures and missing component identity testing.
High risk -
FoodGreat Enterprise - Group - Inc.
FDA says Great Enterprise Group, a Honolulu food importer, had no Foreign Supplier Verification Program for sauces, bamboo shoots and rice sticks.
High risk -
DrugsRevlon Group Holdings, LLC
FDA cited Revlon's Oxford, NC over-the-counter drug plant for failing to test talc for asbestos and weak quality oversight.
High risk -
DrugsUmendra Life Sciences Private Limited
Umendra Life Sciences, an Indian maker of OTC talc-containing drugs, failed CGMP on talc testing and asbestos control, FDA says.
High risk -
DrugsPLZ Corp
FDA warned PLZ Corp over an OTC talc drug made in Mississauga without asbestos testing and with deficient component controls.
High risk -
DrugsAsanuma Corporation - Sagamihara Factory
FDA warned Japan's Asanuma Sagamihara factory, an OTC drug maker, that its talc was never tested for asbestos.
High risk -
DrugsShantou Qiwei Industry Co., LTD
FDA warns Shantou Qiwei, a Chinese OTC drug maker, that it never tested talc for asbestos, making its products adulterated.
High risk -
DrugsZydus Lifesciences Limited
FDA warns Zydus Lifesciences over untested asbestos in talc used in its prescription drugs and altered lab data at its Himachal Pradesh plant.
High risk -
DrugsMacau-Union Pharmaceutical Limited
Macau-Union Pharmaceutical failed CGMP and sold unapproved, misbranded Bamboo Pharmacy OTC pain rubs in the U.S.
High risk -
FoodBest Buy Bones, Inc.
Best Buy Bones pet treats were found with Salmonella and serious animal-food safety and CGMP violations.
High risk -
DrugsActive Cosmetics Manufacturing Inc.
FDA cited Active Cosmetics Manufacturing for releasing topical OTC drugs after microbial contamination without thorough investigations.
High risk -
DrugsRespilon Production S.R.O.
FDA found Respilon, a Czech OTC drug maker, lacked ingredient identity testing, stability data and process validation.
Medium -
DrugsFoshan Miwei Cosmetics Co., Ltd.
FDA warns Foshan Miwei Cosmetics over manufacturing practice failures and unapproved, misbranded over-the-counter (OTC) sunscreen drugs; drugs on import alert.
High risk -
DrugsLexia LLC
FDA cited Lexia for manufacturing violations in an OTC topical pain relief drug, including missing release and component testing.
High risk -
DrugsRC Outsourcing, LLC
FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.
High risk -
DrugsPurolea Cosmetics Lab
Purolea Cosmetics Lab drug products were adulterated by insanitary conditions and manufacturing failures, and two Dermveda products are unapproved new drugs.
High risk -
DrugsMicrobiological Testing & Consulting, LLC
FDA warned contract testing lab Microbiological Testing & Consulting over CGMP violations in drug product microbiological testing.
High risk -
DrugsYangzhou H&R Plastic Daily Chemical Co., Ltd.
Yangzhou H&R Plastic Daily Chemical, a Chinese contract manufacturer, lacked release testing and CGMP controls for its OTC drug.
High risk -
DrugsFlowchem Pharma Private Limited
FDA warned India's Flowchem Pharma over dirty API equipment, exposed materials and untested impurities, and blocked its drug imports.
High risk -
DrugsAQ USA Inc., d.b.a Ross Healthcare Inc.
FDA warns AQ USA/Ross Healthcare over current good manufacturing practice violations in drugs, including missing microbial testing and inadequate component and stability controls.
High risk -
DrugsIntegrity Partners Group
FDA warns Integrity Partners Group about manufacturing failures at its Chemisphere drug plant, including inadequate testing, supplier verification, cleaning, and process validation.
High risk -
DrugsLiquidCapsule Manufacturing, LLC
LiquidCapsule Manufacturing failed CGMP (current good manufacturing practice) for OTC drugs, including component identity testing and process validation failures.
High risk -
DrugsMedinatura New Mexico, Inc.
FDA cited Medinatura New Mexico for drug manufacturing rule violations, including weak component testing and cleaning.
High risk -
DrugsSklar Personal Care Inc.
Sklar Personal Care’s drug facility failed CGMP (current good manufacturing practice), including untested raw materials and inadequate cleaning, process validation, and quality oversight.
High risk -
DrugsCDL Services, Inc. DBA Technichem
FDA warned CDL Services (Technichem), an Anaheim OTC drug maker, that it released hand sanitizer and hand soap batches without testing.
High risk -
DrugsDeVere Manufacturing Inc.
FDA warned DeVere Manufacturing in Janesville, Wisconsin, that its OTC hand sanitizers are adulterated after a June 2025 inspection found CGMP failures.
High risk -
DrugsCdymax India Pharma Private Limited
FDA warned Cdymax (India) Pharma that its Bangalore API plant had inadequate out-of-specification investigations and unvalidated test methods, making its APIs adulterated.
High risk -
DrugsSeema International
FDA warns Seema International over unclean API equipment, missing stability data, and quality-unit failures after inspection; APIs adulterated.
High risk -
DrugsDermaRite Industries, LLC
DermaRite failed CGMP and sold unapproved, misbranded OTC topical drugs, FDA says.
High risk -
DrugsUriel Pharmacy, Inc.
Uriel Pharmacy's homeopathic ampule drugs are unapproved new drugs and were made under serious CGMP violations.
High risk -
DrugsMiers Laboratories, Ltd
FDA warns Miers Laboratories over manufacturing violations and places import alert on its drugs.
High risk -
DrugsThe Tranzonic Companies/Innocore Sales & Marketing Inc.
FDA says Innocore Sales & Marketing, an over-the-counter drug manufacturer, lacked finished-product, component, stability and quality-unit controls.
High risk